lamivudine · Medicine question

How does chronic hepatitis B or C affect the risk of liver adverse events during combination HIV therapy containing lamivudine?

Name: How does chronic hepatitis B or C affect the risk of liver adverse events during combination HIV therapy containing lamivudine?
Published: 2026-11-08T01:55:36.802Z

iatroX medicinesPublished 8 November 2026

The answer

Answer

Patients with chronic hepatitis B or C receiving combination HIV therapy containing lamivudine have an increased risk of severe and potentially fatal liver adverse events.

Sources for this answer

Epivir Oral SolutionViiV Healthcare UK Ltd · emc · SmPC §4.4 Special warnings and precautions for use · Version 45Document updated 24 March 2025

Sources checked 8 November 2026

loading page…

Answer

Sources for this answer

Answer

Sources for this answer

More questions about lamivudine